Coloplast As Sp/Adr (CLPBY) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Coloplast A/s Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.016 Thank you, and good morning, and welcome to our Q1 25-26 conference call. 00:00:05.016 -- 00:00:08.219 I'm Lars Rasmussen, interim CEO of Codoplast, 00:00:08.219 -- 00:00:13.344 and I'm joined by CFO Anders Lonning Skogård and our investor relations team. 00:00:13.344 -- 00:00:17.448 We will start with a short presentation by Anders and myself, and then open up for questions. 00:00:17.448 -- 00:00:20.571 And please turn to slide number three. 00:00:20.571 -- 00:00:26.016 We delivered 6% organic revenue growth and 3% EBIT growth in constant currencies 00:00:26.016 -- 00:00:28.280 before special items. 00:00:28.280 -- 00:00:33.765 Return on invested capital after tax and before special items landed at 15% on 00:00:33.765 -- 00:00:36.065 par with 00:00:39.129 -- 00:00:44.273 last year's adjusted figure. We had a soft start to the year as expected. 00:00:44.273 -- 00:00:47.116 However, with a significant 00:00:47.116 -- 00:00:52.220 more turbulent quarter in caresses than we would have anticipated. 00:00:52.220 -- 00:00:57.184 I'll get back to that in a moment. For the year, we maintain our guidance of around 7% 00:00:57.184 -- 00:01:02.486 organic growth. We'll lower our growth expectations for Kerasis to around 00:01:02.486 -- 00:01:03.988 10% 00:01:03.988 -- 00:01:08.777 amidst significant market uncertainty in the outpatient setting, 00:01:08.777 -- 00:01:13.525 but raise our outlook for interventional reality to high single digits following a strong 00:01:13.525 -- 00:01:16.831 start and improved outlook for the year. 00:01:16.831 -- 00:01:20.357 Before we dive further into the quarterly performance and outlook for the year, let me 00:01:20.357 -- 00:01:23.140 begin with a brief comment on our leadership team. 00:01:23.140 -- 00:0...